{"id":781,"date":"2026-02-05T00:00:00","date_gmt":"2026-02-05T08:00:00","guid":{"rendered":"https:\/\/www.getasecondopinion.ai\/blog\/?p=781"},"modified":"2026-02-04T23:33:22","modified_gmt":"2026-02-05T07:33:22","slug":"fda-approves-darzalex-faspro-as-part-of-a-new-first-line-quadruplet-regimen-for-multiple-myeloma","status":"publish","type":"post","link":"https:\/\/www.getasecondopinion.ai\/blog\/medications\/new-drugs\/fda-approves-darzalex-faspro-as-part-of-a-new-first-line-quadruplet-regimen-for-multiple-myeloma\/","title":{"rendered":"FDA Approves Darzalex Faspro as Part of a New First\u2011Line Quadruplet Regimen for Multiple Myeloma"},"content":{"rendered":"\n<p>Multiple myeloma is a type of blood cancer that affects plasma cells &#8211; specialized white blood cells that help the body fight infections. For years, treatment options have steadily improved, but the newest development marks one of the most meaningful steps forward yet. The U.S. Food and Drug Administration (FDA) has approved a new four\u2011drug (quadruplet) regimen that includes Darzalex Faspro for adults newly diagnosed with multiple myeloma who are not eligible for a stem cell transplant. This approval expands the use of a therapy that has already reshaped the treatment landscape and now strengthens its role even further.<\/p>\n\n\n\n<p>This update matters because it gives patients access to a more powerful combination of medicines earlier in their treatment journey. Early, deeper responses to therapy are strongly linked to better long\u2011term outcomes, and this new regimen &#8211; known as D\u2011VRd &#8211; has shown impressive results in clinical trials.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>What the New Approval Covers<\/strong><\/h2>\n\n\n\n<p>The FDA has approved Darzalex Faspro (a subcutaneous form of daratumumab) to be used alongside three existing medications:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Velcade (bortezomib)<\/strong><\/li>\n\n\n\n<li><strong>Revlimid (lenalidomide)<\/strong><\/li>\n\n\n\n<li><strong>Dexamethasone<\/strong><\/li>\n<\/ul>\n\n\n\n<p>Together, these four drugs form the regimen called D\u2011VRd. This combination is now cleared for adults who are newly diagnosed with multiple myeloma and are not eligible for an autologous stem cell transplant.<\/p>\n\n\n\n<p>This is the first anti\u2011CD38 antibody\u2011based quadruplet regimen approved for all newly diagnosed patients, regardless of transplant eligibility. That distinction is important because it broadens access to a more effective therapy for a wider group of people.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Why This Approval Matters<\/strong><\/h2>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>A stronger start to treatment<\/strong><\/h3>\n\n\n\n<p>Multiple myeloma is typically treated in phases, and the first phase &#8211; called first\u2011line therapy &#8211; is crucial. The goal is to reduce the amount of cancer in the body as much as possible. The new D\u2011VRd regimen has been shown to produce deeper responses than the previous standard three\u2011drug combination (VRd alone).<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>A more convenient formulation<\/strong><\/h3>\n\n\n\n<p>Darzalex Faspro is given as an under\u2011the\u2011skin injection rather than an IV infusion. This can shorten treatment time and reduce the burden on patients who already spend many hours in medical settings.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Better long\u2011term potential<\/strong><\/h3>\n\n\n\n<p>The earlier and more completely cancer cells are eliminated, the better the chances of delaying disease progression. The new regimen significantly improves the rate of \u201cminimal residual disease negativity,\u201d a measure of how thoroughly cancer cells have been cleared from the bone marrow.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>What the CEPHEUS Trial Showed<\/strong><\/h2>\n\n\n\n<p>The FDA approval is based on results from the large Phase 3 <strong>CEPHEUS trial<\/strong>, which enrolled 395 patients who were newly diagnosed and not eligible for a stem cell transplant. Participants were randomly assigned to receive either:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>D\u2011VRd (Darzalex Faspro + VRd)<\/strong><\/li>\n\n\n\n<li><strong>VRd alone<\/strong><\/li>\n<\/ul>\n\n\n\n<p>The results were striking:<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Minimal Residual Disease (MRD) Negativity<\/strong><\/h3>\n\n\n\n<p>MRD negativity means that extremely sensitive tests cannot detect any cancer cells in the bone marrow. Achieving MRD negativity is associated with longer survival and better long\u2011term outcomes.<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><strong>Outcome<\/strong><\/td><td><strong>D\u2011VRd<\/strong><\/td><td><strong>VRd Alone<\/strong><\/td><\/tr><tr><td>MRD\u2011negativity rate at 22 months<\/td><td>52.3%<\/td><td>34.8%<\/td><\/tr><tr><td>Sustained MRD\u2011negativity for 12+ months<\/td><td>42.6%<\/td><td>25.3%<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<div class=\"wp-block-group unauthenticated invisible has-global-padding is-layout-constrained wp-container-core-group-is-layout-675f737c wp-block-group-is-layout-constrained\" style=\"padding-right:var(--wp--preset--spacing--30);padding-left:var(--wp--preset--spacing--30)\">\n<div class=\"wp-block-group cta-background has-background has-global-padding is-content-justification-left is-layout-constrained wp-container-core-group-is-layout-64f51f8a wp-block-group-is-layout-constrained\" style=\"border-style:none;border-width:0px;border-radius:30px;background-color:#f6fffc;padding-top:var(--wp--preset--spacing--30);padding-right:var(--wp--preset--spacing--30);padding-bottom:var(--wp--preset--spacing--30);padding-left:var(--wp--preset--spacing--30);box-shadow:var(--wp--preset--shadow--natural);background-image:url(&apos;https:\/\/getasecondopinion.ai\/blog\/wp-content\/uploads\/2025\/10\/cta-background-03b.webp&apos;);background-position:100% 100%;background-repeat:no-repeat;background-size:contain;background-attachment:scroll;\">\n<div class=\"wp-block-group has-global-padding is-layout-constrained wp-container-core-group-is-layout-153751c2 wp-block-group-is-layout-constrained\" style=\"padding-bottom:10px\">\n<h3 class=\"wp-block-heading has-text-align-center has-accent-1-color has-text-color has-link-color has-large-font-size wp-elements-9363713a6feba58457096f3ce3e67f32\">Stop Overpaying for Meds.<\/h3>\n\n\n\n<p>Coupons aren\u2019t your only option &#8211; see if safer, more effective, and lower-cost alternatives are available. It\u2019s fast, personalized, and 100% free. <strong><a href=\"https:\/\/getasecondopinion.ai\/intro-summary\" target=\"_blank\" rel=\"noreferrer noopener\">Learn More \u2192<\/a><\/strong><\/p>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Progression\u2011Free Survival (PFS)<\/strong><\/h3>\n\n\n\n<p>PFS measures how long patients live without their cancer worsening.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>The quadruplet regimen reduced the risk of disease progression or death by <strong>40%<\/strong> compared to VRd alone.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Depth of Response<\/strong><\/h3>\n\n\n\n<p>At nearly five years of follow\u2011up, <strong>81.2%<\/strong> of patients receiving D\u2011VRd achieved a complete response or better, compared with <strong>61.6%<\/strong> of those receiving VRd alone.<\/p>\n\n\n\n<p>These results show that adding Darzalex Faspro to the standard three\u2011drug regimen significantly improves outcomes across multiple measures that matter to patients and families.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>What This Means for Patients and Families<\/strong><\/h2>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>More effective treatment from the start<\/strong><\/h3>\n\n\n\n<p>The earlier multiple myeloma is controlled, the better the long\u2011term outlook. This new regimen gives patients a stronger chance of achieving deep remission early in their treatment.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>A therapy that works for more people<\/strong><\/h3>\n\n\n\n<p>Not everyone is eligible for a stem cell transplant due to age, health conditions, or personal choice. This approval ensures that those patients still have access to a highly effective first\u2011line option.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>A shift toward more personalized cancer care<\/strong><\/h3>\n\n\n\n<p>The use of MRD negativity as a primary endpoint in the CEPHEUS trial reflects a growing trend in cancer research: measuring how thoroughly a treatment clears cancer cells, not just how long it delays progression. This helps doctors better understand which therapies offer the strongest long\u2011term benefits.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>A more manageable treatment experience<\/strong><\/h3>\n\n\n\n<p>Because Darzalex Faspro is given as an injection rather than an IV infusion, patients may spend less time in the clinic. This can make a meaningful difference in quality of life, especially for those who require frequent treatments.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Safety Considerations<\/strong><\/h2>\n\n\n\n<p>Like all cancer treatments, the D\u2011VRd regimen comes with potential side effects. The FDA notes several important warnings and precautions, including:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Hypersensitivity reactions<\/li>\n\n\n\n<li>Infections<\/li>\n\n\n\n<li>Neutropenia (low white blood cell count)<\/li>\n\n\n\n<li>Thrombocytopenia (low platelet count)<\/li>\n\n\n\n<li>Cardiac toxicity in patients with AL amyloidosis<\/li>\n<\/ul>\n\n\n\n<p>These risks are not new &#8211; they are consistent with what is already known about the individual drugs in the regimen. Healthcare teams monitor patients closely and adjust treatment as needed.<\/p>\n\n\n\n<div class=\"wp-block-group unauthenticated invisible has-global-padding is-layout-constrained wp-container-core-group-is-layout-675f737c wp-block-group-is-layout-constrained\" style=\"padding-right:var(--wp--preset--spacing--30);padding-left:var(--wp--preset--spacing--30)\">\n<div class=\"wp-block-group cta-background has-background has-global-padding is-content-justification-left is-layout-constrained wp-container-core-group-is-layout-64f51f8a wp-block-group-is-layout-constrained\" style=\"border-style:none;border-width:0px;border-radius:30px;background-color:#fff6eb;padding-top:var(--wp--preset--spacing--30);padding-right:var(--wp--preset--spacing--30);padding-bottom:var(--wp--preset--spacing--30);padding-left:var(--wp--preset--spacing--30);box-shadow:var(--wp--preset--shadow--natural);background-image:url(&apos;https:\/\/getasecondopinion.ai\/blog\/wp-content\/uploads\/2025\/10\/cta-background-02.webp&apos;);background-position:100% 100%;background-repeat:no-repeat;background-size:contain;background-attachment:scroll;\">\n<div class=\"wp-block-group has-global-padding is-layout-constrained wp-container-core-group-is-layout-9d2deb30 wp-block-group-is-layout-constrained\" style=\"padding-top:0px;padding-right:0px;padding-bottom:10px\">\n<h3 class=\"wp-block-heading has-text-align-center has-accent-1-color has-text-color has-link-color has-large-font-size wp-elements-e1a2b4d20c009cbe1ac01729b645a8a1\">Experiencing Side Effects? <br>Let\u2019s Rethink Your Meds.<\/h3>\n\n\n\n<p>Explore treatment options that may work better for your body &#8211; with fewer side effects and lower costs. It\u2019s fast, free, and tailored to you. <strong><a href=\"https:\/\/getasecondopinion.ai\/intro-summary\" target=\"_blank\" rel=\"noreferrer noopener\">Learn More \u2192<\/a><\/strong><\/p>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>How This Approval Fits Into the Bigger Picture<\/strong><\/h2>\n\n\n\n<p>Darzalex Faspro has rapidly become one of the most important therapies in multiple myeloma. It now has twelve FDA\u2011approved indications, including five for newly diagnosed disease. This latest approval strengthens its role as a foundational therapy across the entire treatment spectrum.<\/p>\n\n\n\n<p>The quadruplet regimen is also the first to receive FDA approval based on a study that used MRD negativity as its primary endpoint. This milestone may influence how future multiple myeloma treatments are evaluated and approved.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Looking Ahead<\/strong><\/h2>\n\n\n\n<p>The approval of D\u2011VRd represents a meaningful step forward for people facing multiple myeloma. It offers a more powerful first\u2011line option, improves the chances of deep and lasting remission, and expands access to effective therapy for those who cannot undergo a stem cell transplant.<\/p>\n\n\n\n<p>As research continues, more advances are expected &#8211; especially in the areas of targeted therapies, immune\u2011based treatments, and personalized medicine. For now, this new regimen provides renewed hope and a stronger foundation for patients beginning their treatment journey.<\/p>\n\n\n\n<div class=\"wp-block-group unauthenticated invisible has-global-padding is-layout-constrained wp-container-core-group-is-layout-675f737c wp-block-group-is-layout-constrained\" style=\"padding-right:var(--wp--preset--spacing--30);padding-left:var(--wp--preset--spacing--30)\">\n<div class=\"wp-block-group cta-background has-custom-off-white-background-color has-background has-global-padding is-content-justification-left is-layout-constrained wp-container-core-group-is-layout-64f51f8a wp-block-group-is-layout-constrained\" style=\"border-style:none;border-width:0px;border-radius:30px;padding-top:var(--wp--preset--spacing--30);padding-right:var(--wp--preset--spacing--30);padding-bottom:var(--wp--preset--spacing--30);padding-left:var(--wp--preset--spacing--30);box-shadow:var(--wp--preset--shadow--natural);background-image:url(&apos;https:\/\/getasecondopinion.ai\/blog\/wp-content\/uploads\/2025\/09\/cta-background-01.webp&apos;);background-position:100% 100%;background-repeat:no-repeat;background-size:contain;background-attachment:scroll;\">\n<div class=\"wp-block-group has-global-padding is-layout-constrained wp-container-core-group-is-layout-153751c2 wp-block-group-is-layout-constrained\" style=\"padding-bottom:10px\">\n<h3 class=\"wp-block-heading has-text-align-center has-accent-1-color has-text-color has-link-color has-large-font-size wp-elements-b6fe6b9c1e90c3ca0e3d22a4a0e21d9e\">Better Treatment, Lower Cost &#8211; No Catch.<\/h3>\n\n\n\n<p>Find safer, more effective medications with fewer side effects &#8211; often for less money. It\u2019s fast, free, and personalized. <strong><a href=\"https:\/\/getasecondopinion.ai\/intro-summary\" target=\"_blank\" rel=\"noreferrer noopener\">Learn More \u2192<\/a><\/strong><\/p>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Sources (2)<\/strong><\/h2>\n\n\n\n<ol class=\"wp-block-list\">\n<li>DARZALEX FASPRO\u2011based quadruplet regimen approved in the U.S. for newly diagnosed patients with multiple myeloma who are transplant ineligible\u00a0 <br><a href=\"https:\/\/www.jnj.com\/media-center\/press-releases\/darzalex-faspro-based-quadruplet-regimen-approved-in-the-u-s-for-newly-diagnosed-patients-with-multiple-myeloma-who-are-transplant-ineligible\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/www.jnj.com\/media-center\/press-releases\/darzalex-faspro-based-quadruplet-regimen-approved-in-the-u-s-for-newly-diagnosed-patients-with-multiple-myeloma-who-are-transplant-ineligible<\/a>\u00a0<\/li>\n\n\n\n<li>FDA approves daratumumab and hyaluronidase\u2011fihj with bortezomib, lenalidomide, and dexamethasone for newly diagnosed multiple myeloma\u00a0<br><a href=\"https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-daratumumab-and-hyaluronidase-fihj-bortezomib-lenalidomide-and-dexamethasone-newly\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-daratumumab-and-hyaluronidase-fihj-bortezomib-lenalidomide-and-dexamethasone-newly<\/a>\u00a0<\/li>\n<\/ol>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Multiple myeloma is a type of blood cancer that affects plasma cells &#8211; specialized white blood cells that help the body fight infections. For years, treatment options have steadily improved, but the newest development marks one of the most meaningful steps forward yet. The U.S. Food and Drug Administration (FDA) has approved a new four\u2011drug [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":782,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[35],"tags":[589,586,587,371,591,588,590,584,585,583],"class_list":["post-781","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-new-drugs","tag-cancer-drug-approval","tag-cancer-therapy-news","tag-darzalex-faspro","tag-fda-approval","tag-healthcare-innovation","tag-medical-blog-header","tag-multiple-myeloma-treatment","tag-myeloma-breakthrough","tag-oncology-updates","tag-quadruplet-regimen"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>FDA Approves Darzalex Faspro as Part of a New First\u2011Line Quadruplet Regimen for Multiple Myeloma - Get a Second Opinion<\/title>\n<meta name=\"description\" content=\"FDA approves Darzalex Faspro in new quadruplet regimen for multiple myeloma, expanding frontline treatment options.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.getasecondopinion.ai\/blog\/medications\/new-drugs\/fda-approves-darzalex-faspro-as-part-of-a-new-first-line-quadruplet-regimen-for-multiple-myeloma\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FDA Approves Darzalex Faspro as Part of a New First\u2011Line Quadruplet Regimen for Multiple Myeloma - Get a Second Opinion\" \/>\n<meta property=\"og:description\" content=\"FDA approves Darzalex Faspro in new quadruplet regimen for multiple myeloma, expanding frontline treatment options.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.getasecondopinion.ai\/blog\/medications\/new-drugs\/fda-approves-darzalex-faspro-as-part-of-a-new-first-line-quadruplet-regimen-for-multiple-myeloma\/\" \/>\n<meta property=\"og:site_name\" content=\"Get a Second Opinion\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/getasecondopinion\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-05T08:00:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.getasecondopinion.ai\/blog\/wp-content\/uploads\/2026\/02\/Darzalex-Faspro.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1536\" \/>\n\t<meta property=\"og:image:height\" content=\"1024\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"G2O\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"G2O\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/medications\\\/new-drugs\\\/fda-approves-darzalex-faspro-as-part-of-a-new-first-line-quadruplet-regimen-for-multiple-myeloma\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/medications\\\/new-drugs\\\/fda-approves-darzalex-faspro-as-part-of-a-new-first-line-quadruplet-regimen-for-multiple-myeloma\\\/\"},\"author\":{\"name\":\"G2O\",\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/#\\\/schema\\\/person\\\/9fbb863e981c8982fb301d0644843b20\"},\"headline\":\"FDA Approves Darzalex Faspro as Part of a New First\u2011Line Quadruplet Regimen for Multiple Myeloma\",\"datePublished\":\"2026-02-05T08:00:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/medications\\\/new-drugs\\\/fda-approves-darzalex-faspro-as-part-of-a-new-first-line-quadruplet-regimen-for-multiple-myeloma\\\/\"},\"wordCount\":1080,\"publisher\":{\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/medications\\\/new-drugs\\\/fda-approves-darzalex-faspro-as-part-of-a-new-first-line-quadruplet-regimen-for-multiple-myeloma\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/Darzalex-Faspro.jpg\",\"keywords\":[\"cancer drug approval\",\"cancer therapy news\",\"Darzalex Faspro\",\"FDA Approval\",\"healthcare innovation\",\"medical blog header\",\"multiple myeloma treatment\",\"myeloma breakthrough\",\"oncology updates\",\"quadruplet regimen\"],\"articleSection\":[\"New Drugs\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/medications\\\/new-drugs\\\/fda-approves-darzalex-faspro-as-part-of-a-new-first-line-quadruplet-regimen-for-multiple-myeloma\\\/\",\"url\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/medications\\\/new-drugs\\\/fda-approves-darzalex-faspro-as-part-of-a-new-first-line-quadruplet-regimen-for-multiple-myeloma\\\/\",\"name\":\"FDA Approves Darzalex Faspro as Part of a New First\u2011Line Quadruplet Regimen for Multiple Myeloma - Get a Second Opinion\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/medications\\\/new-drugs\\\/fda-approves-darzalex-faspro-as-part-of-a-new-first-line-quadruplet-regimen-for-multiple-myeloma\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/medications\\\/new-drugs\\\/fda-approves-darzalex-faspro-as-part-of-a-new-first-line-quadruplet-regimen-for-multiple-myeloma\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/Darzalex-Faspro.jpg\",\"datePublished\":\"2026-02-05T08:00:00+00:00\",\"description\":\"FDA approves Darzalex Faspro in new quadruplet regimen for multiple myeloma, expanding frontline treatment options.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/medications\\\/new-drugs\\\/fda-approves-darzalex-faspro-as-part-of-a-new-first-line-quadruplet-regimen-for-multiple-myeloma\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/medications\\\/new-drugs\\\/fda-approves-darzalex-faspro-as-part-of-a-new-first-line-quadruplet-regimen-for-multiple-myeloma\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/medications\\\/new-drugs\\\/fda-approves-darzalex-faspro-as-part-of-a-new-first-line-quadruplet-regimen-for-multiple-myeloma\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/Darzalex-Faspro.jpg\",\"contentUrl\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/Darzalex-Faspro.jpg\",\"width\":1536,\"height\":1024,\"caption\":\"FDA approval announcement for Darzalex Faspro, shown with medical items including syringe, vial, capsules, and stethoscope on blue background.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/medications\\\/new-drugs\\\/fda-approves-darzalex-faspro-as-part-of-a-new-first-line-quadruplet-regimen-for-multiple-myeloma\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Insights\",\"item\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Medications\",\"item\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/category\\\/medications\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"New Drugs\",\"item\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/category\\\/medications\\\/new-drugs\\\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"FDA Approves Darzalex Faspro as Part of a New First\u2011Line Quadruplet Regimen for Multiple Myeloma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/#website\",\"url\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/\",\"name\":\"Get a Second Opinion\",\"description\":\"Insights\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/#organization\",\"name\":\"Get a Second Opinion\",\"url\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/getasecondopinion.ai\\\/blog\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/G2O-logo-full.png\",\"contentUrl\":\"https:\\\/\\\/getasecondopinion.ai\\\/blog\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/G2O-logo-full.png\",\"width\":1000,\"height\":129,\"caption\":\"Get a Second Opinion\"},\"image\":{\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/getasecondopinion\",\"https:\\\/\\\/www.instagram.com\\\/getasecondopinion\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/#\\\/schema\\\/person\\\/9fbb863e981c8982fb301d0644843b20\",\"name\":\"G2O\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/21b03bf2b185bfb0dd4d13c2214225de3355abca7b52e424ee73d37b573644a0?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/21b03bf2b185bfb0dd4d13c2214225de3355abca7b52e424ee73d37b573644a0?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/21b03bf2b185bfb0dd4d13c2214225de3355abca7b52e424ee73d37b573644a0?s=96&d=mm&r=g\",\"caption\":\"G2O\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"FDA Approves Darzalex Faspro as Part of a New First\u2011Line Quadruplet Regimen for Multiple Myeloma - Get a Second Opinion","description":"FDA approves Darzalex Faspro in new quadruplet regimen for multiple myeloma, expanding frontline treatment options.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.getasecondopinion.ai\/blog\/medications\/new-drugs\/fda-approves-darzalex-faspro-as-part-of-a-new-first-line-quadruplet-regimen-for-multiple-myeloma\/","og_locale":"en_US","og_type":"article","og_title":"FDA Approves Darzalex Faspro as Part of a New First\u2011Line Quadruplet Regimen for Multiple Myeloma - Get a Second Opinion","og_description":"FDA approves Darzalex Faspro in new quadruplet regimen for multiple myeloma, expanding frontline treatment options.","og_url":"https:\/\/www.getasecondopinion.ai\/blog\/medications\/new-drugs\/fda-approves-darzalex-faspro-as-part-of-a-new-first-line-quadruplet-regimen-for-multiple-myeloma\/","og_site_name":"Get a Second Opinion","article_publisher":"https:\/\/www.facebook.com\/getasecondopinion","article_published_time":"2026-02-05T08:00:00+00:00","og_image":[{"width":1536,"height":1024,"url":"https:\/\/www.getasecondopinion.ai\/blog\/wp-content\/uploads\/2026\/02\/Darzalex-Faspro.jpg","type":"image\/jpeg"}],"author":"G2O","twitter_card":"summary_large_image","twitter_misc":{"Written by":"G2O","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.getasecondopinion.ai\/blog\/medications\/new-drugs\/fda-approves-darzalex-faspro-as-part-of-a-new-first-line-quadruplet-regimen-for-multiple-myeloma\/#article","isPartOf":{"@id":"https:\/\/www.getasecondopinion.ai\/blog\/medications\/new-drugs\/fda-approves-darzalex-faspro-as-part-of-a-new-first-line-quadruplet-regimen-for-multiple-myeloma\/"},"author":{"name":"G2O","@id":"https:\/\/www.getasecondopinion.ai\/blog\/#\/schema\/person\/9fbb863e981c8982fb301d0644843b20"},"headline":"FDA Approves Darzalex Faspro as Part of a New First\u2011Line Quadruplet Regimen for Multiple Myeloma","datePublished":"2026-02-05T08:00:00+00:00","mainEntityOfPage":{"@id":"https:\/\/www.getasecondopinion.ai\/blog\/medications\/new-drugs\/fda-approves-darzalex-faspro-as-part-of-a-new-first-line-quadruplet-regimen-for-multiple-myeloma\/"},"wordCount":1080,"publisher":{"@id":"https:\/\/www.getasecondopinion.ai\/blog\/#organization"},"image":{"@id":"https:\/\/www.getasecondopinion.ai\/blog\/medications\/new-drugs\/fda-approves-darzalex-faspro-as-part-of-a-new-first-line-quadruplet-regimen-for-multiple-myeloma\/#primaryimage"},"thumbnailUrl":"https:\/\/www.getasecondopinion.ai\/blog\/wp-content\/uploads\/2026\/02\/Darzalex-Faspro.jpg","keywords":["cancer drug approval","cancer therapy news","Darzalex Faspro","FDA Approval","healthcare innovation","medical blog header","multiple myeloma treatment","myeloma breakthrough","oncology updates","quadruplet regimen"],"articleSection":["New Drugs"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.getasecondopinion.ai\/blog\/medications\/new-drugs\/fda-approves-darzalex-faspro-as-part-of-a-new-first-line-quadruplet-regimen-for-multiple-myeloma\/","url":"https:\/\/www.getasecondopinion.ai\/blog\/medications\/new-drugs\/fda-approves-darzalex-faspro-as-part-of-a-new-first-line-quadruplet-regimen-for-multiple-myeloma\/","name":"FDA Approves Darzalex Faspro as Part of a New First\u2011Line Quadruplet Regimen for Multiple Myeloma - Get a Second Opinion","isPartOf":{"@id":"https:\/\/www.getasecondopinion.ai\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.getasecondopinion.ai\/blog\/medications\/new-drugs\/fda-approves-darzalex-faspro-as-part-of-a-new-first-line-quadruplet-regimen-for-multiple-myeloma\/#primaryimage"},"image":{"@id":"https:\/\/www.getasecondopinion.ai\/blog\/medications\/new-drugs\/fda-approves-darzalex-faspro-as-part-of-a-new-first-line-quadruplet-regimen-for-multiple-myeloma\/#primaryimage"},"thumbnailUrl":"https:\/\/www.getasecondopinion.ai\/blog\/wp-content\/uploads\/2026\/02\/Darzalex-Faspro.jpg","datePublished":"2026-02-05T08:00:00+00:00","description":"FDA approves Darzalex Faspro in new quadruplet regimen for multiple myeloma, expanding frontline treatment options.","breadcrumb":{"@id":"https:\/\/www.getasecondopinion.ai\/blog\/medications\/new-drugs\/fda-approves-darzalex-faspro-as-part-of-a-new-first-line-quadruplet-regimen-for-multiple-myeloma\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.getasecondopinion.ai\/blog\/medications\/new-drugs\/fda-approves-darzalex-faspro-as-part-of-a-new-first-line-quadruplet-regimen-for-multiple-myeloma\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.getasecondopinion.ai\/blog\/medications\/new-drugs\/fda-approves-darzalex-faspro-as-part-of-a-new-first-line-quadruplet-regimen-for-multiple-myeloma\/#primaryimage","url":"https:\/\/www.getasecondopinion.ai\/blog\/wp-content\/uploads\/2026\/02\/Darzalex-Faspro.jpg","contentUrl":"https:\/\/www.getasecondopinion.ai\/blog\/wp-content\/uploads\/2026\/02\/Darzalex-Faspro.jpg","width":1536,"height":1024,"caption":"FDA approval announcement for Darzalex Faspro, shown with medical items including syringe, vial, capsules, and stethoscope on blue background."},{"@type":"BreadcrumbList","@id":"https:\/\/www.getasecondopinion.ai\/blog\/medications\/new-drugs\/fda-approves-darzalex-faspro-as-part-of-a-new-first-line-quadruplet-regimen-for-multiple-myeloma\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Insights","item":"https:\/\/www.getasecondopinion.ai\/blog\/"},{"@type":"ListItem","position":2,"name":"Medications","item":"https:\/\/www.getasecondopinion.ai\/blog\/category\/medications\/"},{"@type":"ListItem","position":3,"name":"New Drugs","item":"https:\/\/www.getasecondopinion.ai\/blog\/category\/medications\/new-drugs\/"},{"@type":"ListItem","position":4,"name":"FDA Approves Darzalex Faspro as Part of a New First\u2011Line Quadruplet Regimen for Multiple Myeloma"}]},{"@type":"WebSite","@id":"https:\/\/www.getasecondopinion.ai\/blog\/#website","url":"https:\/\/www.getasecondopinion.ai\/blog\/","name":"Get a Second Opinion","description":"Insights","publisher":{"@id":"https:\/\/www.getasecondopinion.ai\/blog\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.getasecondopinion.ai\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.getasecondopinion.ai\/blog\/#organization","name":"Get a Second Opinion","url":"https:\/\/www.getasecondopinion.ai\/blog\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.getasecondopinion.ai\/blog\/#\/schema\/logo\/image\/","url":"https:\/\/getasecondopinion.ai\/blog\/wp-content\/uploads\/2025\/09\/G2O-logo-full.png","contentUrl":"https:\/\/getasecondopinion.ai\/blog\/wp-content\/uploads\/2025\/09\/G2O-logo-full.png","width":1000,"height":129,"caption":"Get a Second Opinion"},"image":{"@id":"https:\/\/www.getasecondopinion.ai\/blog\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/getasecondopinion","https:\/\/www.instagram.com\/getasecondopinion"]},{"@type":"Person","@id":"https:\/\/www.getasecondopinion.ai\/blog\/#\/schema\/person\/9fbb863e981c8982fb301d0644843b20","name":"G2O","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/21b03bf2b185bfb0dd4d13c2214225de3355abca7b52e424ee73d37b573644a0?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/21b03bf2b185bfb0dd4d13c2214225de3355abca7b52e424ee73d37b573644a0?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/21b03bf2b185bfb0dd4d13c2214225de3355abca7b52e424ee73d37b573644a0?s=96&d=mm&r=g","caption":"G2O"}}]}},"_links":{"self":[{"href":"https:\/\/www.getasecondopinion.ai\/blog\/wp-json\/wp\/v2\/posts\/781","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.getasecondopinion.ai\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.getasecondopinion.ai\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.getasecondopinion.ai\/blog\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.getasecondopinion.ai\/blog\/wp-json\/wp\/v2\/comments?post=781"}],"version-history":[{"count":1,"href":"https:\/\/www.getasecondopinion.ai\/blog\/wp-json\/wp\/v2\/posts\/781\/revisions"}],"predecessor-version":[{"id":783,"href":"https:\/\/www.getasecondopinion.ai\/blog\/wp-json\/wp\/v2\/posts\/781\/revisions\/783"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.getasecondopinion.ai\/blog\/wp-json\/wp\/v2\/media\/782"}],"wp:attachment":[{"href":"https:\/\/www.getasecondopinion.ai\/blog\/wp-json\/wp\/v2\/media?parent=781"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.getasecondopinion.ai\/blog\/wp-json\/wp\/v2\/categories?post=781"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.getasecondopinion.ai\/blog\/wp-json\/wp\/v2\/tags?post=781"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}